- 询价
- 2025年08月13日
14 年金牌会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 相关疾病：
其他疾病
- ATCC Number：
CRL-5811™
- 生长状态：
悬浮生长
- 库存：
大量
- 年限：
stage E
- 细胞形态：
上皮样
- 物种来源：
人
- 是否是肿瘤细胞：
1
- 运输方式：
冻存运输
- 器官来源：
肺
| Designations: | NCI-H526 [H526] | ||
| Depositors: | AF Gazdar, JD Minna | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | round clusters in suspension | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: lung Tumor Stage: stage E Disease: carcinoma; variant small cell lung cancer Derived from metastatic site: bone marrow |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Restrictions: | The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233. | ||
| Receptors: | insulin-like growth factor II (IGF II); bombesin | ||
| Tumorigenic: | Yes | ||
| Oncogene: | myc +; myb +; fes +; fms +; raf +; ras + | ||
| DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 11 D13S317: 13 D16S539: 9 D5S818: 11 D7S820: 9,12 THO1: 6,8 TPOX: 8,11 vWA: 16,17 |
||
| Age: | 55 years adult | ||
| Gender: | male | ||
| Ethnicity: | Caucasian | ||
| Comments: | This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a bone marrow metastasis taken from a patient prior to therapy. NCI-H526 expresses elevated levels of 2 biochemical markers of SCLC: neuron specific enolase and the brain isoenzyme of creatine kinase. They do not express L-dopa carboxylase or bombesin-like immunoreactivity. These cells express the c-kit gene as well as the N-myc gene, but not c-myc or L-myc. N-myc is amplified and p75 c-myb expression was observed. NCI-H526 also expresses the proto-oncogenes N-ras, Ki-ras, Ha-ras, and c-raf1. Only trace amounts of the retinoblastoma susceptibility gene, RB mRNA were detected. RB protein was not detected. The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung. Abnormally sized mRNA was present. The line has a reported colony-forming efficiency of 4.2% in soft agarose. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases. |
||
| Preservation: | Culture medium, 95%; DMSO, 5% | ||
| Doubling Time: | 36 hrs | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 purified DNA:ATCC CRL-5811D |
||
| References: | 1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 22250: Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917 22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 22725: Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988 23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 23065: Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028 23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 23104: Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 23106: Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933 23162: Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893 23227: Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043 23386: Bepler G, et al. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372, 1988. PubMed: 2470067 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.. 24389: . . Lung Cancer 4: 155-161, 1988. |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
NCI-H526
询价
